UPDATE 1-Hikma trims FY revenue forecast on Advair U.S. launch delay

May 19 (Reuters) - Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.